Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467435 · ClinicalTrials.gov registry record · Phase 1
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
A Phase 1 study of Thyroid Eye Disease, sponsored by Peter Timoney.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT06467435 is a Phase 1 study of Thyroid Eye Disease that is actively recruiting participants, run by Peter Timoney. The registered enrollment target is 13 participants, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06467435, a Phase 1 study of Thyroid Eye Disease, is actively recruiting participants, sponsored by Peter Timoney.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.
Conditions Studied
Interventions
- DRUG Kamuvudine-9
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-11-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06467435
The ClinicalTrials.gov registry entry for NCT06467435 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (88% lower). The listed sponsor is Peter Timoney, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which Kamuvudine-9 is the first listed.
NCT06467435 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT06467435 about?
NCT06467435 is a clinical study titled "Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)". The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 w...
What is the current status of trial NCT06467435?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-11-06. Estimated completion is 2027-08.
What conditions does trial NCT06467435 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06467435?
The interventions under investigation include: Kamuvudine-9 (DRUG).
Who is sponsoring clinical trial NCT06467435?
This trial is sponsored by Peter Timoney, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06467435 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.